Date: 2016-12-05
Type of
information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the American Association for Cancer Research (AACR) Annual Meeting
Company: Kymab (UK)
Product: KY1005
Action
mechanism: monoclonal antibody. KY1005 is a fully human monoclonal antibody that binds to OX40L and blocks it from activating OX40, a protein that induces prolonged response in T-cells of the immune system, which can lead to the damaging effects of acute GvHD and autoimmune diseases.
Disease: acute graft-versus-host-disease (GvHD)
Therapeutic
area: Transplantation
Country:
Trial
details:
Latest
news:
- • On December 5, 2016, Kymab announced early stage results of its new antibody treatment, KY1005, which showed an improvement in post-transplant survival in an animal model of acute graft-versus-host-disease (GvHD), a common and potentially deadly complication of bone marrow transplants. The results, obtained in a joint project led by Dr. Leslie Kean, Associate Director of the Ben Towne Center for Childhood Cancer Research at Seattle Children’s Research Institute and Dr. Phil Bland-Ward, VP of Non-Clinical Development at Kymab, were published in a poster presentation at the American Society of Hematology Annual Meeting in San Diego, California.
- The research teams showed that KY1005 dampened the exaggerated immune response that causes acute GvHD following bone marrow transplants. Most strikingly, when combined with an established, yet on its own insufficient, therapy to prevent acute GvHD, KY1005 completely prevented signs of acute GvHD. All animals survived to the end of the study. The reported experiments looked at the effect of KY1005 in a model of acute GvHD, closely simulating the processes leading to human GvHD after bone marrow transplant. Without effective prophylaxis, the transplanted immune system launches a vigorous attack against the tissues of the transplant recipient, which was inhibited by KY1005.
- The survival rate occurred when Kymab’s antibody KY1005 was administered with one of these immune suppressants, Rapamycin, a prophylactic regimen. The two molecules interfered with separate cellular pathways resulting in the enhanced effect.
Is
general: Yes
